Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
Javed Butler, Faı̈ez Zannad, Gerasimos Filippatos, Stefan D. Anker, Milton Packer
Abstract
Sodium-glucose co-transporter-2 (SGLT2) inhibitors exert favourable effects on the heart and kidney that cannot be explained by their glucose-lowering effect. 2]
Topics & Concepts
MedicineEjection fractionTransporterHeart failureSodiumInternal medicineCardiologyPharmacologyBiochemistryChemistryOrganic chemistryGeneDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and Research